Co-treatment of the spheroids with the CSF from patients with MS and NIBR189, the EBI2 antagonist, or desmosterol, CH25H inhibitor, rescued the CSF induced downregulation of VE-cadherin. We also examined the expression of EBI2 and CH25H and CYP7B1 in the CSF treated spheroids and again found only HSD3B7 affected by the treatments (Fig. 3E). Here, GPR183 is linked to myeloid sarcoma.